Recent Updates
Recently added Catalysts
JAZZ

Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming virtual investor conferences:...

Key Takeaway: DUBLIN , Sept. 8, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will participate in the following upcoming virtual investor conferences: BofA Virtual Global Healthcare Conference 2021 on Wednesday, September 15, 2021 Cantor Virtu
Price reaction · baseline $134.99 (2021-09-07 close) · hit after-hours · 1 other JAZZ headline(s) in the window, move may be shared
day 0 close
0%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
2.1%
average across 9 past catalysts
Lead asset
GWP42004
Phase 2 · Diabetes Mellitus, Type 2

Full Press Release Details

DUBLIN , Sept. 8, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the company will participate in the following upcoming virtual investor conferences:
BofA Virtual Global Healthcare Conference 2021 on Wednesday, September 15, 2021
Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (NASDAQ: JAZZ ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.
Investors: Andrea N. Flynn , Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email protected] Ireland +353 1 634 3211 U.S. +1 650 496 2717
Last updated: Sep 8, 2021